Helsingborg-based Acorai, a company specializing in heart failure management devices, has secured €4.2 million ($4.5 million USD) in new funding.
The investment, led by the European Innovation Council (EIC) Fund, Taiwan Medical University, and private investors, will support the completion of clinical studies and regulatory approvals in the US and Europe.
Advertisement
Transforming Cardiac Care with Non-Invasive Technology
Acorai is developing a non-invasive intracardiac pressure monitoring device designed to improve heart failure management for over 64 million patients globally. Built on the patented SAVE Sensor System, the device uses seismic, acoustic, visual, and electrical sensors to gather detailed cardiac data. This data is analyzed in real time using a machine learning engine trained on one of the largest clinical datasets.
“Acorai is committed to reshaping cardiac care with non-invasive solutions,” said CEO Filip Peters. “This funding is a transformative step toward making our technology available to millions of heart failure patients.”
Regulatory and Commercialization Milestones
Acorai has achieved several key milestones, including:
- FDA Breakthrough Device Designation: Facilitates faster approval processes and participation in the FDA’s TAP Pilot Program.
- CAPTURE-HF Study Completion: Involves over 1,600 participants across 20 hospitals in six countries.
- Plans to launch commercially by 2026 following regulatory approvals.
The company is preparing to raise additional funding in 2025 to scale clinical validation and early commercialization efforts.
EIC Fund Backing
The EIC Fund, known for supporting disruptive technologies, has provisioned an additional $6 million for future equity financing rounds. Peters emphasized the importance of this partnership: “The EIC Fund’s involvement underscores our potential to lead in non-invasive cardiac care.”
Aiming for Global Impact
With this funding, Acorai is poised to accelerate its clinical and regulatory efforts, aiming to revolutionize heart failure management with its innovative, non-invasive solutions. The device has the potential to improve outcomes for millions of patients while reducing the burden on healthcare systems worldwide.
